A Prospective, Open-Label, Multicenter Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Trial Profile

A Prospective, Open-Label, Multicenter Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Malignant melanoma; Rhabdomyosarcoma; Solid tumours
  • Focus Diagnostic use
  • Sponsors Cardinal Health; Navidea Biopharmaceuticals
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2021.
    • 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2021.
    • 27 Jun 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top